Dengvaxia Market Report 2026

Dengvaxia Market Overview

• The Dengvaxia market growth in the historic period has been driven by recurring dengue outbreaks, high disease burden in tropical regions • Market expansion is supported by expansion of vaccination coverage, increasing climate driven mosquito spread • Growth Driver: Rising Dengue Incidence Drives Growth In The Market • Asia-Pacific was the largest region in 2025 and Latin America is the fastest growing region.

What Is Covered Under Dengvaxia Market?

Dengvaxia is a recombinant vaccine developed to protect against dengue fever, a viral illness transmitted by Aedes mosquitoes, by stimulating the immune system to produce a targeted response that helps prevent infection and severe complications, contributing to public health efforts in regions where dengue is endemic. The main types of dengvaxia are dengvaxia and others. Dengvaxia is a specific vaccine developed to prevent dengue fever. It is the first dengue vaccine approved for use and is designed to provide immunity against the virus that causes dengue. It helps reduce the severity and frequency of dengue episodes, making it an important tool in areas prone to dengue outbreaks. Dengvaxia has been used in various countries where dengue is prevalent to protect high-risk populations. These are distributed through hospitals, clinics, and public health programs and are used in multiple clinical indications such as prevention in previously infected individuals, protection in high-risk regions, traveler immunization, and pediatric and adolescent use.

What Is The Dengvaxia Market Growth Forecast?

The dengvaxia market size is expected to see rapid growth in the next few years. It will grow to $473.95 million in 2030 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to expansion of vaccination coverage, increasing climate driven mosquito spread, growth in public health funding, improved vaccine delivery infrastructure, rising travel related immunization demand. Major trends in the forecast period include expansion of dengue vaccination programs, growing focus on endemic disease prevention, rising public health immunization campaigns, increased surveillance of mosquito-borne diseases, strengthening of pediatric and adolescent vaccination.

Global Dengvaxia Market Segmentation

1) By Type: Dengvaxia, Other Types 2) By Distribution Channel: Hospitals, Clinics, Public Health Programs 3) By Clinical Indication: Prevention In Previously Infected Individuals, Protection In High-Risk Regions, Traveler Immunization, Pediatric And Adolescent Use

What Are The Drivers Of The Dengvaxia Market?

The high incidence of dengue is expected to propel the growth of the dengvaxia market going forward. Dengue is a viral infection transmitted by Aedes mosquitoes, causing flu-like symptoms, severe pain, and in severe cases, potentially life-threatening complications such as dengue hemorrhagic fever or dengue shock syndrome. The increasing prevalence of dengue is due to climate change, urbanization, increased travel, and expanding mosquito breeding grounds, leading to higher infection rates and greater demand for prevention and treatment. Dengvaxia helps prevent dengue as it is an effective vaccine that stimulates the immune system to produce a protective response against the dengue virus, reducing the risk of infection and severe complications and contributing to better public health outcomes in endemic areas. For instance, in June 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, the Americas reported over 9.7 million dengue cases, double the 4.6 million cases in 2023. Puerto Rico declared a public health emergency with 1,498 cases, and 745 cases were reported among U.S. travelers. Therefore, the high incidence of dengue is driving growth in the dengvaxia industry. Rising international travel is expected to propel the growth of the dengvaxia market going forward. International travel refers to the act of traveling between different countries for purposes such as tourism, business, or education. Rising international travel increases the risk of spreading infectious diseases, including dengue, which drives the demand for preventive measures like vaccines. Dengvaxia is used in rising international travel to protect travelers from contracting dengue in endemic regions and reduce the risk of disease transmission across borders. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, in 2023, the number of international visits to the UK saw a significant increase, rising from 31.2 million in 2022 to 38.0 million. Therefore, rising international travel will drive the growth of the dengvaxia industry. Growing healthcare expenditures are expected to accelerate the growth of the dengvaxia market going forward. Healthcare expenditures refer to the financial resources allocated by governments, private entities, or individuals for the provision of healthcare services, medical treatments, and health-related activities. Growth in healthcare expenditures is driven by the increasing demand for medical services, advancements in healthcare technology, and the rising prevalence of chronic diseases, which leads to greater investment in healthcare infrastructure and treatments. Healthcare expenditure on Dengvaxia focuses on prevention, aiming to reduce the long-term costs of treating dengue and managing outbreaks. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, growing healthcare expenditures will drive the growth of the dengvaxia industry.

Key Players In The Global Dengvaxia Market

Major companies operating in the dengvaxia market are Sanofi Pasteur Inc.

Regional Insights

Asia-Pacific was the largest region in the dengvaxia market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Dengvaxia Market?

The dengvaxia market consists of sales of dengvaxia (CYD-TDV), disposable syringes and needles, pre-filled syringes of dengvaxia, and unit-dose packaging. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dengvaxia Market Report 2026?

The dengvaxia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dengvaxia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.